 "Dr Reddy's falls 9% in two days on disappointing Q1 results")
Dr Reddy’s Laboratories dipped 6% to Rs 2,470, extending its previous day’s 3% decline on BSE, after the company reported disappointing set of numbers for the quarter ended June 2017 (Q1FY18).
The consolidated net profit for the pharmaceutical company more- than-halved to Rs 59 crore in Q1FY18 against Rs 126 crore in the same quarter year ago. Revenue during the quarter under review grew 3% to Rs 3,316 crore from Rs 3,235 crore in year ago quarter.
Analysts on an average had expected profit of Rs 307 crore on revenues of Rs 3,399 crore for the quarter.
“Our first-quarter results have been below expectations. While headwinds in the form of price erosion due to US customer consolidation continue a lower contribution from new product launches in the US and the GST implementation in India also impacted our performance,” Dr Reddy's Co-Chairman and Chief Executive Officer GV Prasad said.
“We are yet to see the full impact of the genericization; however, launch of gVytorin, gAngiomax and gDoxil along with a recovery in the domestic business should halt a slide in margins. On the regulatory front, we continue to believe that Srikakulam woes may be resolved by the year-end; however, Bachupally's Form 483 remain a overhang given that it generates >50% of the US topline, in our view,” analysts at Antique Stock Broking said in Q1 results review and reduce target price to Rs 2,700.
Analysts at Emkay Global Financial Services, maintain HOLD rating, see some rebound in earnings across the generic space, especially FY19 onwards, simply due to the high R&D spend and pent up pipelines. However there remain longer term apprehensions on the structural dynamics of the generic business.
At 9:45 am; the stock was trading 5.5% lower at Rs 2,478 on BSE, as compared to 0.56% decline in the S&P BSE Sensex. It hit a 52-week low of Rs 2,382 on May 29, 2017 on BSE in intra-day trade.
The consolidated net profit for the pharmaceutical company more- than-halved to Rs 59 crore in Q1FY18 against Rs 126 crore in the same quarter year ago. Revenue during the quarter under review grew 3% to Rs 3,316 crore from Rs 3,235 crore in year ago quarter.
Analysts on an average had expected profit of Rs 307 crore on revenues of Rs 3,399 crore for the quarter.
“Our first-quarter results have been below expectations. While headwinds in the form of price erosion due to US customer consolidation continue a lower contribution from new product launches in the US and the GST implementation in India also impacted our performance,” Dr Reddy's Co-Chairman and Chief Executive Officer GV Prasad said.
“We are yet to see the full impact of the genericization; however, launch of gVytorin, gAngiomax and gDoxil along with a recovery in the domestic business should halt a slide in margins. On the regulatory front, we continue to believe that Srikakulam woes may be resolved by the year-end; however, Bachupally's Form 483 remain a overhang given that it generates >50% of the US topline, in our view,” analysts at Antique Stock Broking said in Q1 results review and reduce target price to Rs 2,700.
Analysts at Emkay Global Financial Services, maintain HOLD rating, see some rebound in earnings across the generic space, especially FY19 onwards, simply due to the high R&D spend and pent up pipelines. However there remain longer term apprehensions on the structural dynamics of the generic business.
At 9:45 am; the stock was trading 5.5% lower at Rs 2,478 on BSE, as compared to 0.56% decline in the S&P BSE Sensex. It hit a 52-week low of Rs 2,382 on May 29, 2017 on BSE in intra-day trade.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%